What does Banisteriopsis caapi do on its own without DMT?

On its own, B. caapi provides β-carboline alkaloids—harmine, harmaline, and tetrahydroharmine—that inhibit MAO-A, raising serotonin and dopamine levels in the brain. Traditional practitioners report mild visionary and introspective states from the vine alone, attributed to elevated endogenous monoamine levels rather than exogenous psychedelics; however, these effects are less intense than the full ayahuasca brew and have not been objectively measured in clinical studies.

Is Banisteriopsis caapi legal to possess or use as a supplement?

In most countries, including the United States, the plant Banisteriopsis caapi itself is not a scheduled controlled substance, as it does not contain DMT; its β-carboline alkaloids (harmine, harmaline) occupy a legal grey area that varies by jurisdiction. However, preparations combining it with DMT-containing plants constitute a scheduled substance in many countries, and some nations (e.g., France, Hungary) explicitly schedule harmaline; users should verify local regulations before purchase or use.

Can you take Banisteriopsis caapi with antidepressants?

Combining B. caapi with antidepressants—particularly SSRIs, SNRIs, tricyclics, or MAOIs—carries a serious risk of serotonin syndrome, a potentially life-threatening condition characterized by agitation, hyperthermia, tachycardia, and neuromuscular abnormalities. Because harmaline alone achieves MAO-A IC50 of 4.54 nM (extremely potent), even small doses of the vine can substantially block serotonin metabolism; this combination is considered a hard contraindication and must be avoided.

What is the difference between harmine and harmaline in Banisteriopsis caapi?

Both harmine and harmaline are β-carboline alkaloids and reversible MAO-A inhibitors found in B. caapi, but harmaline (IC50 4.54 nM) is more potent than harmine at MAO-A inhibition and is present at lower concentrations (0.12–0.59% vs. harmine's 1.26–3.71% dry weight). Harmaline preferentially suppresses proinflammatory cytokines at low micromolar concentrations in microglial cells, while harmine at high concentrations (>75.5 µM) becomes cytotoxic and pro-oxidant, illustrating distinct dose-response profiles despite structural similarity.

Are there any clinical trials proving Banisteriopsis caapi works for depression or Parkinson's disease?

No clinical trials have been conducted on isolated B. caapi for depression or Parkinson's disease as of the current literature review; mechanistic hypotheses are based on preclinical data showing MAO-A inhibition and dopamine release enhancement (at 2.5 mg/mL in rat striatal slices). Evidence from ayahuasca studies—which combine B. caapi with DMT—cannot be attributed to the vine alone, and the absence of pharmacokinetic and dose-finding data in humans means therapeutic claims remain speculative and unsupported by regulatory-grade evidence.

What is the typical dose range for Banisteriopsis caapi extract, and how is it usually consumed?

Traditional preparations typically use 5–15 grams of dried vine material brewed as a decoction, though standardized extracts may provide 1–3 grams equivalent per serving. Dosing depends on alkaloid content (harmine/harmaline concentration), with clinical interest focusing on doses that achieve meaningful MAO-A inhibition without excessive monoamine elevation. Always start at lower doses to assess individual tolerance, as effects vary based on extraction method and individual sensitivity to MAOI activity.

Who should avoid Banisteriopsis caapi due to safety concerns, and what medical conditions contraindicate its use?

People with uncontrolled hypertension, heart arrhythmias, or hypersensitivity to monoamine modulators should avoid Banisteriopsis caapi, as MAO-A inhibition raises catecholamine levels. Pregnant and nursing women should not use it due to lack of safety data and potent pharmacological effects. Individuals with bipolar disorder, psychotic disorders, or those taking stimulants should consult a healthcare provider before use, as monoamine elevation carries theoretical risks in these populations.

How does the alkaloid profile (harmine vs. harmaline ratio) affect Banisteriopsis caapi's potency and effects?

While both harmine and harmaline inhibit MAO-A with comparable potency (IC50 ~4.54 nM), harmaline demonstrates superior anti-inflammatory activity at physiologically relevant concentrations (≥2.5 µM), suggesting extracts with higher harmaline content may offer additional cytokine-modulating benefits. The ratio between these alkaloids influences the overall pharmacological profile—harmine-predominant extracts may emphasize monoamine effects, while harmaline-rich preparations may provide stronger immune-modulatory activity. Commercial extracts vary significantly in alkaloid composition, making standardization important for consistent therapeutic effect.

Yagé

Banisteriopsis caapi contains β-carboline alkaloids—harmine (1.26–3.71%), harmaline (0.12–0.59%), and tetrahydroharmine—that act as potent reversible inhibitors of monoamine oxidase A (MAO-A), with harmaline achieving an IC50 of 4.54 nM. Preclinical data in BV-2 microglial cells demonstrate dose-dependent suppression of proinflammatory cytokines IL-2, IL-6, IL-17, and TNF by harmaline and select fractions at concentrations ≥2.5 µM, while no isolated clinical trials in humans have been completed.

Category: Amazonian Evidence: 1/10 Tier: Preliminary

Origin & History

Banisteriopsis caapi is a large woody liana native to the tropical rainforests of the Amazon Basin, distributed across Brazil, Peru, Colombia, Ecuador, and Bolivia, thriving in humid lowland and montane jungle environments. The vine grows along riverbanks and forest margins, often cultivated in indigenous gardens (chakras) where it may reach decades of age before harvest. Indigenous communities selectively propagate elder vines believed to be more potent, harvesting mature stems that contain the highest concentrations of β-carboline alkaloids.

Historical & Cultural Context

Banisteriopsis caapi has been used for at least several centuries—and likely millennia—by Amazonian indigenous peoples including the Shipibo-Conibo, Asháninka, Shuar, Cofán, and numerous other nations as the foundational ingredient of ayahuasca, a sacred visionary brew central to healing ceremonies, spiritual initiation, and community governance. The vine itself, referred to as 'yagé' in Colombia and parts of Ecuador and as 'caapi' in Brazil, is personified as a sentient plant teacher in many indigenous cosmologies, and its cultivation, harvest, and preparation are surrounded by elaborate ritual protocols including dietary restrictions (dietas) and periods of social seclusion. Preparation typically involves harvesting older vine sections, beating or scraping the bark to expose the inner cambium, and boiling with water—sometimes in combination with Psychotria viridis (chacruna) leaves—for extended periods to produce a potent decoction. The vine first entered Western scientific literature in the mid-19th century through the work of botanist Richard Spruce, and its alkaloid chemistry was characterized in the 20th century by researchers including Claudio Naranjo and, later, Dennis McKenna, whose ethnobotanical and biochemical work helped establish its pharmacological identity.

Health Benefits

- **MAO-A Inhibition and Monoamine Modulation**: Harmine and harmaline reversibly inhibit MAO-A with an IC50 of 4.54 nM and whole-extract IC50 of 1.24 µg/mL, raising synaptic levels of serotonin, dopamine, and norepinephrine by reducing their oxidative catabolism.
- **Anti-inflammatory Activity**: Harmaline (≥2.5 µM) and fraction F5 suppress proinflammatory cytokines IL-2, IL-6, IL-17, and TNF in lipopolysaccharide-stimulated BV-2 microglial cells in a dose-dependent manner, in some cases reducing concentrations to undetectable levels in vitro.
- **Upregulation of Anti-inflammatory Cytokines**: Crude extracts and fraction F1 (0.5–4 µg/mL) elevate IL-4 production, while fraction F2 (64 µg/mL) boosts IL-10, suggesting a dual capacity to suppress pro-inflammatory signals and promote resolving immune responses.
- **Dopaminergic Stimulation**: At 2.5 mg/mL, B. caapi extracts enhance dopamine release from rat striatal slices ex vivo, implicating potential relevance for conditions involving dopaminergic hypofunction such as Parkinson's disease, though human evidence is absent.
- **Antioxidant Properties**: β-Carboline alkaloids in B. caapi exhibit antioxidant activity in preclinical assays, potentially mitigating oxidative stress; paradoxically, harmine at high concentrations (75.5–302 µM) increases reactive oxygen species (ROS) in BV-2 cells, indicating a strongly dose-dependent and biphasic redox profile.
- **Neuroprotective Potential**: Tetrahydroharmine (THH) reduces proinflammatory cytokine levels in microglial cultures at ≥9.3 µM and, together with harmaline, has been hypothesized to support neuronal survival under neuroinflammatory conditions, though this remains unverified in vivo.
- **Traditional Visionary and Psychospiritual Use**: As the MAO-A inhibitory component of ayahuasca, B. caapi enables oral bioavailability of N,N-dimethyltryptamine (DMT) from admixture plants; the vine alone is also reported to induce mild visionary states among indigenous practitioners, attributed to endogenous β-carbolines.

How It Works

The primary mechanism of Banisteriopsis caapi is reversible, competitive inhibition of monoamine oxidase A (MAO-A) by harmine and harmaline, with harmaline exhibiting an IC50 of 4.54 nM—a potency comparable to pharmaceutical reversible MAO-A inhibitors—thereby blocking the oxidative deamination of serotonin, dopamine, and norepinephrine and elevating monoaminergic tone. In neuroinflammatory contexts, harmaline and fraction F5 suppress nuclear factor-kappa B (NF-κB)-mediated transcription of proinflammatory cytokines (IL-2, IL-6, IL-17, TNF) in BV-2 microglial cells at ≥2.5 µM, while crude extract and fraction F1 shift cytokine balance toward the anti-inflammatory mediators IL-4 and IL-10. Harmine at cytotoxic concentrations (75.5–302 µM) disrupts mitochondrial membrane integrity, induces necrotic cell death rather than apoptosis, and elevates intracellular ROS in BV-2 cells within 24 hours, indicating a steep dose-response curve that separates anti-inflammatory from pro-cytotoxic regimes. Tetrahydroharmine (THH) may additionally act as a weak serotonin reuptake inhibitor based on structural analogy, potentially contributing to serotonergic augmentation independently of MAO-A inhibition.

Scientific Research

The body of evidence for isolated B. caapi consists entirely of in vitro cell culture studies (primarily BV-2 murine microglia) and ex vivo rat striatal slice experiments, with no published randomized controlled trials or prospective human studies evaluating the vine as a standalone ingredient. Key preclinical work has characterized cytokine modulation, MAO-A inhibition kinetics, and dopamine release under controlled laboratory conditions, yielding mechanistically informative but clinically non-transferable data. Evidence for broader therapeutic effects—including antidepressant, neuroprotective, or anti-Parkinson actions—is inferred from the pharmacology of isolated harmine and harmaline in rodent models but has not been replicated in human participants using the whole vine extract. The overall evidence base scores low on clinical hierarchy; findings from ayahuasca combination studies (which include DMT-containing Psychotria viridis) cannot be attributed to B. caapi alone and should not be conflated with single-ingredient research.

Clinical Summary

No standalone clinical trials on Banisteriopsis caapi have been identified in the available literature; all human research involves ayahuasca, a multi-ingredient brew whose effects cannot be isolated to B. caapi's β-carboline content. Preclinical in vitro studies establish concentration-dependent anti-inflammatory and MAO-A inhibitory activity with quantifiable IC50 values, but translational extrapolation to human therapeutic doses is unestablished because no pharmacokinetic modeling or bioavailability data for oral ingestion of the vine extract in humans exists. Observational and ceremonial accounts from indigenous and contemporary settings suggest psychoactive and introspective effects from vine-alone preparations, but these are anecdotal and methodologically unsuitable for clinical inference. Confidence in any health outcome claim for isolated B. caapi in humans is currently very low, and therapeutic use should be considered experimental.

Nutritional Profile

As a woody liana bark and stem preparation, Banisteriopsis caapi does not provide meaningful macronutrient content (protein, fat, carbohydrate) in the quantities consumed medicinally or ceremonially. The primary phytochemical constituents are β-carboline alkaloids: harmine (1.26–3.71% dry weight), harmaline (0.12–0.59%), and tetrahydroharmine (THH, concentration variable), along with minor alkaloids and polyphenolic compounds identified by HPLC with exact masses including F1 (174.09 Da, 233.13 Da), F2 (353.17 Da), F3 (304.30 Da), F4 (188.11 Da), and F5 (205.08 Da). Additional standardized markers in dried stem extracts include compounds labeled 1 (0.81–3.93%), 2 (0.50–10.72%), 5 (0.29–3.48%), 8 (0.6–5.4%), and 9 (0.9–7.2%), though their structural identities are not fully characterized in the available literature. Bioavailability of β-carbolines from the decoction in humans is presumed to be moderate to high based on their MAO-inhibitory pharmacological activity in vivo during ayahuasca use, but formal pharmacokinetic studies for isolated B. caapi preparations are lacking.

Preparation & Dosage

- **Traditional Decoction (Yagé/Ayahuasca)**: Mature vine stems (100–200 g fresh weight per person) are crushed and slow-boiled with water for 4–8 hours, sometimes through multiple reductions, to concentrate β-carboline alkaloids; no standardized gram dosage is established for isolated supplemental use.
- **Dried Stem Extract (Research Grade)**: Standardized dried extracts contain harmine 1.26–3.71% and harmaline 0.12–0.59% by dry weight; commercial extracts report harmine at 1.36% and harmaline at 0.24%, used in vitro at 0.5–64 µg/mL—no human equivalent dose is validated.
- **Isolated Alkaloids (Experimental)**: Harmaline and harmine are used in research at 2.5–302 µM in cell assays; no capsule or tablet form with defined alkaloid content has an established clinical dosing regimen for humans.
- **Ceremonial Use Timing**: Traditional ceremonies administer the decoction in the evening in fasting states; this practice is culturally embedded and not equivalent to a nutritional supplement protocol.
- **Standardization Note**: No regulatory agency has established a standardized extract specification or acceptable daily intake for B. caapi as a dietary supplement; any commercial product claiming standardization should be verified by third-party HPLC.

Synergy & Pairings

In the traditional ayahuasca preparation, B. caapi's β-carbolines synergize obligately with Psychotria viridis (or other DMT-containing plants): harmine and harmaline inhibit intestinal and hepatic MAO-A, preventing first-pass degradation of orally ingested DMT and enabling its psychoactive CNS effects—a pharmacokinetic synergy with no equivalent for most botanical stacks. Some practitioners combine B. caapi vine with other Amazonian botanicals such as Mimosa hostilis (jurema) as an alternative DMT source, or with tobacco (Nicotiana rustica) in ritual contexts, though these combinations carry compounded safety risks. From a mechanistic standpoint, stacking B. caapi with antioxidant-rich botanicals such as Uncaria tomentosa (cat's claw) has been proposed to offset the pro-oxidant, cytotoxic effects of harmine at higher concentrations, but this combination has not been evaluated in controlled studies.

Safety & Interactions

Harmine at concentrations of 75.5–302 µM in BV-2 microglial cells reduces cell viability, induces necrosis (rather than apoptosis), and elevates reactive oxygen species after 24 hours, while fraction F4 shows cytotoxicity at ≥10.7 µM, indicating that β-carboline alkaloids at elevated doses carry direct cellular toxicity that may translate to human risk at high intake levels. As potent MAO-A inhibitors, B. caapi preparations carry a clinically significant risk of serotonin syndrome when combined with serotonergic medications including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, triptans, lithium, tramadol, and meperidine; concurrent consumption of tyramine-rich foods (aged cheeses, fermented meats, certain wines) may additionally precipitate hypertensive crises. Contraindications include current use of any monoaminergic psychiatric medication, cardiovascular disease, uncontrolled hypertension, personal or family history of psychosis or bipolar disorder with manic features, and pregnancy or lactation, the latter due to the absence of safety data and theoretical teratogenic risk from alkaloid exposure. No maximum safe dose for humans has been formally established by any regulatory authority, and use outside traditional ceremonial contexts under experienced guidance should be considered high-risk.